CAS: 131707-25-0; Ethyl 6-Bromo-4-[(Dimethylamino)Methyl]-5-Hydroxy-1-Methyl-2-(Phenylsulfanylmethyl)Indole-3-Carboxylate

上下游产品

bis-(dimethylamino)methane 6-bromo-5-hydroxy-1-methyl-2-phenylthiomethylindole-3-carboxylic acid ethyl ester formaldehyd dimethyl amine6-bromo-5-hydroxy-1-methyl-2-phenylthiomethylindole-3-carboxylic acid ethyl ester Arbidol hydr°Chloride

美卡比酯置于甲醇,N-溴代丁二酰亚胺(Nbs),[rhcl2(P-Cymene)]2,溶剂黄146,Potassium Hydroxide体系中,用 N,N-二甲基乙酰胺,水 用作溶剂,化学反应 36.5H,反应生成阿比朵尔
参考文献:一种合成盐酸阿比朵尔中间体的方法
标题:一种合成盐酸阿比朵尔中间体的方法
摘要:一种合成盐酸阿比朵尔中间体的方法,其属于医药中间体技术领域.该方法采用5‑羟基‑1,2‑二甲基吲哚‑3‑羧酸乙酯为原料,经酯化,溴代,苯硫酚化和脱保护,Mannich反应,成盐得到盐酸阿比朵尔.在溴代反应生成最重要的中间体5‑乙酰氧基‑6‑溴‑2‑溴甲基‑1‑甲基吲哚‑3‑羧酸过程中,以(对甲基异丙基苯)‑二氯化钌二聚体为催化剂,Nbs为溴代试剂,Dma用作溶剂代替传统溴素溴代试剂,反应条件温和,反应选择性高以及原料来源方便,同时可以避免溴素对环境的污染,并且新型催化剂不受反应环境影响导致催化活性降低.因此该方法具有副产物少,产率高,生产成本低,安全性高,节省能源等诸多优点,符合绿色反应的现代化工生产要求.

专利信息

专利号:US-10370455-B2
优先权日:2014-12-05
标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
发明人：MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
权利人:IMMUNEXT INC
摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

专利号:WO-2024061972-A1
优先权日:2022-09-20
标 题:Methods and platform for chemical synthesis
发明人：CRONIN LEE; MANZANO SEBASTIÃ?N; ZALESSKIY SERGEY; KITSON PHILIP; WANG HSIN
权利人:UNIV GLASGOW COURT
摘要:The invention relates to a method and apparatus for performing and characterising a chemical synthesis, such as those performed with an automated chemical synthesis platform, including such that are portable platforms, the method comprising the steps of: performing a chemical synthesis in a chemical synthesiser; recording analytical data during the chemical synthesis, and developing a profile for the analytical data recorded over time; and comparing the profile for the chemical synthesis against a reference profile, which reference profile is the analytical data recorded over time for a reference chemical synthesis, wherein the chemical synthesis and the reference chemical synthesis share at least the same reagents and method steps for the same intended product, such as the chemical synthesis and the reference chemical synthesis sharing the same instruction set. The method and apparatus are for intended for use in replication of approved, chemical syntheses based on common reaction platforms.

专利号:US-10065924-B2
优先权日:2014-07-22
标 题 :Preparation and biological evaluation of viridicatumtoxin analogs
发明人：NICOLAOU KYRIACOS C; HALE CHRISTOPHER R H; NILEWSKI CHRISTIAN; IOANNIDOU HERAKLIDIA; EL MARROUNI ABDELLATIF
权利人:UNIV RICE WILLIAM M
摘要:In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.

专利号:WO-2022049567-A3
优先权日:2021-04-28
标题:Synthesis and in silico studies of novel anti-sars-cov sulfonamides as potential inhibitors against covid-19 protein target: sars-cov-2 main protease (m pro )
发明人：AL-SEHEMI ABDULLAH G; CHINNAM SAMPATH; PANNIPARA MEHBOOBALI; YALLUR BASAPPA C; CHIGURUPATI SRIDEVI; GOWDA B H JASWANTH; PAUL KARTHIKA; SHIVANNA CHANDAN RAVANDUR; VARDHARAJULA VENKATA RAMAIAH
权利人:AL SEHEMI ABDULLAH G; CHINNAM SAMPATH; PANNIPARA MEHBOOBALI; YALLUR BASAPPA C; CHIGURUPATI SRIDEVI; GOWDA B H JASWANTH; PAUL KARTHIKA; SHIVANNA CHANDAN RAVANDUR; VARDHARAJULA VENKATA RAMAIAH
摘要:A cluster of pneumonia cases and COVID-19 pandemic that started in Wuhan, China, was caused by novel beta coronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation requires the activity of the main viral protease (Mpro) and thereby, inhibition stops the advancement of the disease. The current invention delivers a potential anti-viral drug candidates docked against COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E.Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of -14.00 kcal/mol.

专利号:US-10562936-B2
优先权日:2015-09-18
标题 :Ligands for integrin αvβ6, synthesis and uses thereof
发明人：KAPP TOBIAS; KESSLER HORST; MALTSEV OLEG
权利人:UNIV MUENCHEN TECH
摘要:Disclosed are compound exhibiting highly active and selective binding to αvβ6 integrin, which are represented by the following general formula (I): Cyclo-(Arg-X1-Asp-X2-X3-X4-X5-X6-X7) (I) wherein the variables groups X to X have the following meanings X1: Ser, Gly, Thr, X2: Leu, lie, Nle, Val, Phe, X3: Gly, Ala, X4: Leu, He, Nle, Val, Phe, Lys, Tyr, Trp, Arg, X5: D-Pro, N-Me-D-lipophilic amino acids, X6: Pro, N-Me-amino acids, N-Me-Lys, N-Me-Lys(Ac), and X7; Ala, Leu, He, Nle, Val, Phe, Tyr, Trp or wherein the sub-sequence -X5-X6- represents a β-turn mimetic differing from the meanings above, or pharmaceutically acceptable salts, esters, solvates, polymorphs or modified forms thereof represented by the following general formula (II): (X0)n1L(X8)n2 wherein Xo represents the compound of the general formula (I) as specified above (excluding one hydrogen atom to allow bonding to the linker), L represents a linker, X8 represents the effector moiety and wherein n1 and n2 are each independently selected from the range of 1 to 5, wherein n1+n2 represents the number of valencies of the linker and is preferably in the range of from 2 to 6, more preferably 3-5, with the proviso that each of n1 and n2 is at least 1, as well as uses therefore in therapy and imaging.

专利号:US-11332498-B2
优先权日:2017-03-17
标 题:Ligands for integrin αVβ8, synthesis and uses thereof
发明人：KESSLER HORST; KAPP TOBIAS; REICHART FLORIAN; MALTSEV OLEG
权利人:UNIV MUENCHEN TECH
摘要:Disclosed are compounds represented by the following general formula (I): Cyclo-(Arg-Gly-Asp-X1-X2-X3-X4-X5) (I) wherein the variables groups X1 to X5 have the following meanings X1: Leu, Ile, Nle, Val, Tyr, Phe; X2: D-amino acid such as D-Pro, N-Me-D-Phe; X3: Pro, N-Me-amino acid such as N-Me-Lys, N-Me-Lys(Ac); Pro-Rx3, N-Me-Lys-Rx4; X4: Gly, Ala, Ser, Thr; X5: Leu, Ala, Tyr, His, Ile, Nle, Val, Phe wherein Pro-Rx3 represents a proline residue that carries at the C-3, C-4 or C-5 carbon atom and preferably the C-4 carbon atom a functional group selected from —NH2, —OH, —NH—Ac, —NH-hexyne, and wherein Lys-Rx4 represents a lysine residue, wherein the ω-amino nitrogen atom carries a group of the formula -L4-R4, wherein L4 is selected from the group consisting of covalent bond, —C(O)—, and —C(O)—O—, . . . , and wherein R4 is selected from the group consisting of —(CH2)n-C≡CH with n=0, 1, 2, 3, 4, 5, 6, 7 or 8, or wherein the sub-sequence -X2-X3- represents a β-turn mimetic diffeωωring from the meanings above, or pharmaceutically acceptable salts, esters, solvates, polymorphs or modified forms thereof represented by the following general formula (II): (X0)n1L(X8)n2 wherein X0 represents the compound of the general formula (I) as specified above (excluding one hydrogen atom to allow bonding to the linker), L represents a linker, X8 represents the effector moiety and wherein n1 and n2 are each independently selected from the range of 1 to 5, preferably such that each of n1 and n2 represents 1, wherein n1+n2 represents the number of valencies of the linker and is preferably in the range of from 2 to 6, more preferably 2-5, with the proviso that each of n1 and n2 is at least 1, as well as uses therefore in therapy and imaging.